QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF) All Versions of this Article: 9/3/314    most recent 15228517-2007-002v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (14) Citing Articles via Google Scholar Google Scholar Articles by Abrey, L. E. Search for Related Content PubMed PubMed Citation Social Bookmarking                   What's this?

Survey of treatment recommendations for anaplastic oligodendroglioma

Memorial Sloan-Kettering Cancer Center, New York, NY, USA (L.E.A., A.B.L., L.M.D.); Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA (D.N.L.); Northwestern University, Evanston, IL, USA (N.P.); Northwestern University, Feinberg School of Medicine, Chicago, IL, USA (J.J.R.); Princess Margaret Hospital, Toronto, Canada (W.M.); Children's Hospital of Los Angeles, Los Angeles, CA, USA (J.F.); London Regional Cancer Centre, London, Canada (D.R.M.); and University of Calgary, Calgary, Canada (J.G.C.)

Address correspondence to Lauren E. Abrey, Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA (abreyl{at}mskcc.org).

Anaplastic oligodendroglioma is a malignant brain tumor uniquely sensitive to treatment with both chemotherapy and radiotherapy. There are few prospective clinical trials for newly diagnosed patients and multiple approaches to the treatment of these patients. This study explored the recommended treatment offered by experts in neuro-oncology. A Web-based survey was developed and distributed to 800 members of the Society of Neuro-Oncology (SNO) who had an e-mail address listed with SNO. Questions addressed use of molecular genetic information and treatment recommendations. A total of 99 clinical SNO members (20%) responded. The majority reported practicing at an academic center in the United States. Two-thirds of respondents see more than five patients with newly diagnosed anaplastic oligodendroglioma annually. Molecular genetic testing was requested for more than 75% of patients, and the results significantly influenced treatment recommendations (p = 0.000003). Regardless of molecular genetic status, the most commonly recommended treatment was the use of concurrent temozolomide and radiotherapy followed by adjuvant temozolomide (18%-34%). The current survey demonstrates that although neuro-oncologists have embraced the use of molecular genetic studies in newly diagnosed anaplastic oligodendroglioma, treatment recommendations vary widely and are often independent of the molecular data.

Key Words: 1p • 19q • anaplastic oligodendroglioma • molecular genetic studies • radiotherapy • survey • temozolomide • treatment recommendations

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Snuderl, A. F. Eichler, K. L. Ligon, Q. U. Vu, M. Silver, R. A. Betensky, A. H. Ligon, P. Y. Wen, D. N. Louis, and A. J. Iafrate Polysomy for Chromosomes 1 and 19 Predicts Earlier Recurrence in Anaplastic Oligodendrogliomas with Concurrent 1p/19q Loss Clin. Cancer Res., October 15, 2009; 15(20): 6430 - 6437. [Abstract] [Full Text] [PDF]

				M. A. Vogelbaum, B. Berkey, D. Peereboom, D. Macdonald, C. Giannini, J. H. Suh, R. Jenkins, J. Herman, P. Brown, D. T. Blumenthal, et al. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131 Neuro-oncol, January 1, 2009; 11(2): 167 - 175. [Abstract] [Full Text] [PDF]

				A. B. Lassman Management of Newly Diagnosed Anaplastic Oligodendrogliomas ASCO Educational Book, January 1, 2009; 2009(1): 85 - 89. [Abstract] [Full Text] [PDF]